Search Results

In GPCR drug discovery, a single mistaken assumption can derail an entire program. Terry Kenakin reframes one of pharmacology’s most foundational ideas: the difference between competitive Inside the Lesson: Antagonist Behavior by the Numbers Terry walks through both the pharmacologic and If you want to avoid costly misinterpretations and strengthen your pharmacology toolkit, Terry’s Corner Brief today  ➤   #GPCRantagonism #CompetitiveAntagonists #NonCompetitiveAntagonists #DoseResponseCurve #Pharmacology

Teams equipped with deep GPCR pharmacology insights make different decisions. The sections below synthesize the key topics addressed during the AMA and highlight the GPCR pharmacology This is a core GPCR pharmacology insight:ligand → receptor → G protein is never the entire story. These are core GPCR pharmacology insights for preventing interpretive drift as programs move toward in GPCR innovation is accelerating, and those who invest in deeper GPCR pharmacology insights today will

2026 GPCR Pharmacology AMA: Receptor Theory, Biased Signaling & Assay Interpretation The first GPCR Pharmacology The objective is straightforward: Make mechanistic pharmacology easier to access, revisit, and apply Biased Signaling Terry Kenakin, Ph.D., Professor of Pharmacology at the University of North Carolina Access the white paper here Why Terry’s Pharmacology Corner Mechanistic understanding evolves. Forty years of pharmacological expertise — organized into a year-round framework for serious GPCR scientists

Terry's Corner - New Course on Pharmacologic Models The latest Terry’s Corner unlocks clinical forecasting in the full newsletter   Secure Your Access Now ➤ 🗣️ “Thank you for bringing this (Principles of Pharmacology GPCR University Learner Dr. GPCR Podcast - Surviving Discovery’s Gauntlet Dr. Listen Now – Real Lessons from a GPCR Expert ➤ The future of GPCR isn’t waiting. GPCR Team Read Full Edition ➤

GPCR, a nonprofit organization serving the global G protein-coupled receptor (GPCR) research community research and GPCR drug discovery. GPCR. GPCR Dr. GPCR supports scientists and organizations advancing GPCR biology and GPCR-targeted drug discovery.

as HEK293 cells enable scalable pharmacological assays, but they simplify the cellular context in which pharmacology into more physiologically relevant environments. iPSC-derived cardiomyocytes allow signaling Reserve your spot ➤ GPCR Pharmacology: Open Problems and Discussion Binding assays and functional assays GPCR Dr. GPCR brings together scientists working across GPCR biology, pharmacology, and drug discovery to examine

industry-standard GPCR assay platforms that enable rigorous pharmacological characterization and confident GPCR . proven assay platforms, deep pharmacological expertise, and expert-driven context that supports better GPCR Dr. are trusted by leading pharmaceutical companies worldwide to generate high-quality, decision-enabling pharmacological

If your work touches GPCR pharmacology, these insights aren’t optional—they’re essential. Upcoming events:  Adhesion GPCR Workshop; GRC—Transporters, Ion Channels & GPCRs; MPGPCR Joint Satellite Career opportunities:  Senior/Principal Scientist—GPCR Pharmacology; Principal Scientist—In Vitro Pharmacology Terry’s Corner: GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures Discovery collapses GPCR Podcast: Chemical Probes for GPCR Imaging with Dr.

GPCR and Revvity. GPCR internalization isn’t just a trafficking readout—it’s pharmacology. pharmacology) was not transactional. GPCR   Dr. GPCR X Revvity Collaboration ⸻ Want more like this? 👉 Join the Dr. GPCR Premium Ecosystem  for behind-the-scenes access to GPCR innovators, exclusive deep-dives, and practical

for pharmacological screening, but they have a structural limitation when signaling outcomes depend pharmacology into disease-relevant environments, with dilated cardiomyopathy as a concrete model system Whether a molecule binds at the orthosteric or allosteric site determines its pharmacological behavior and κ-opioid receptors, acting differently at each — a concrete illustration of how receptor-specific pharmacology GPCR Dr. GPCR is the intelligence and community platform for GPCR scientists.

discovery teams from advancing compounds based on artifacts of expression systems rather than intrinsic pharmacology If the assay threshold is too high, real pharmacology becomes invisible. Whole-Cell Responses: A Historical Complication Historically, pharmacology relied on whole-cell or tissue Strategic Implications for Drug Hunters Quantifying receptor selectivity correctly does more than refine pharmacological Why Terry’s Corner Terry’s Pharmacology Corner delivers weekly lectures from Dr.

Each week we highlight the decisions that move GPCR projects forward—from pharmacology essentials to Years of chemistry, photophysics, and pharmacology condensed into one breakthrough: pHSense , a reagent They translated a fundamental principle of chemistry into a usable platform for pharmacology—showing GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need The pace of GPCR innovation is accelerating.

Yet, any pharmacologist who’s pushed beyond textbook theory knows: biology rarely plays fair. Schild analysis turns receptor pharmacology into detective work, spotlighting mechanistic fingerprints Modern pharmacology has powerful modeling software, yet Schild analysis remains the litmus test for mechanism Watch the course trailer 👇 Why Terry’s Corner Weekly pharmacology lectures by Dr. GPCR innovation is accelerating—those who act now will define tomorrow’s breakthroughs.

Every R&D team is under the same pressure: deliver validated targets, clean pharmacology, and translatable Allosteric Interactions Still Matter Orthosteric and allosteric interactions have been in pharmacology learn why this distinction is not just theory, but a practical framework to design cleaner, smarter pharmacology Equip your team with this literacy now to design cleaner pharmacology and accelerate smarter, safer programs GPCR members save  50%+  (check your Weekly News code).

Hello GPCR Minds,   This week, you'll learn all about Terry’s Pharmacology Corner, your new learning space focused on GPCR pharmacology. GPCR Updates Learn Pharmacology That Drives Discovery  – From Dr. Terry Kenakin   Terry’s Corner is your space focused on GPCR pharmacology designed just for you.   GPCR Team

pharmacology How orphan GPCRs and emerging receptor families are expanding the druggable target space Allosteric Modulation and the Microcircuit Model of GPCR Pharmacology Understanding GPCRs as allosteric From In Vitro to In Vivo: Closing the Translational Gap in GPCR Pharmacology Even a well-characterized In vivo GPCR pharmacology  occurs in the context of receptor crosstalk, tissue-specific expression patterns As assay technologies continue to evolve and as the de-orphanization of GPCR pharmacology  accelerates

For over two decades, my work has centered on GPCR pharmacology . The GPCR Data Dilemma: The Lego Bucket Problem I've seen promising GPCR programs generate massive volumes My Approach: Biology, Execution, Systems My consulting approach uniquely blends deep pharmacology expertise GPCR As the co-founder of Dr. GPCR, we've built a global hub connecting over 1,300 GPCR scientists dedicated to this field.

ACCESS data for Structure Therapeutics’ oral GLP-1 agonist aleniglipron, Principal Scientist—In Vitro Pharmacology Terry’s Corner: GPCR Binding Affinity Experiments That Hold Up Orthosteric GPCR binding affinity experiments More new courses arrive weekly in 2026, expanding coverage across GPCR pharmacology fundamentals. GPCR Podcast: When GPCR Tools Scale Even the most elegant tools only matter when they scale beyond a pharmacology.

models that better preserve tissue and disease context, and the translational interpretation of receptor pharmacology Together they illustrate how purinergic pharmacology approaches inflammatory pathology from two directions HEK293 systems are powerful tools for scalable pharmacological screening, but they have a structural pharmacology into disease-relevant environments, with dilated cardiomyopathy as a concrete model system Key implications: Signaling outputs depend on biological context, not only receptor pharmacology iPSC

Recognizing, predicting, and leveraging these interactions is the essence of enzyme inhibition pharmacology This lesson reframes enzyme interaction not as background noise, but as a core pharmacological event. Clark , laid the foundation for today’s quantitative pharmacology. Enzyme Inhibition Pharmacology: Orthosteric vs. Pharmacology isn’t just about hitting the receptor—it’s about surviving the enzymes first.

The gap between pharmacological screening and clinical translation has a structural explanation. Translational Pharmacology HEK293 systems have driven pharmacological screening for decades — and for In these systems, receptor pharmacology can be examined alongside disease-relevant phenotypic responses pharmacology into disease-relevant environments, and what the implications are for translational pharmacology The binding mode of a new molecule isn't a footnote in pharmacology.

The Cell Surface Is Only Part of the Story For decades, GPCR pharmacology centered on events at the cell Just Agonists: Antagonists Internalize Receptors Too One of the foundational assumptions in receptor pharmacology The model needs to account for the possibility that both arms of the pharmacological response — activation The same receptor, the same second messenger, but two fundamentally different pharmacological profiles Pharmacological tools such as Dynasore — a GTPase inhibitor of dynamin 1 and 2 — block internalization

Attrition rates in early pharmacology remain painfully high. The High Cost of Pharmacology Gaps Every experienced drug hunter knows this: validation isn’t the problem Terry puts it bluntly: “Once you have a molecule, everything boils down to pharmacology—hit, lead, candidate invaluable for mechanistic understanding—assay volume control, expression system contrasts, predictive pharmacology Corner Terry’s Corner  is a living, growing knowledge hub led by Terry Kenakin—a world authority in pharmacology

Welcome back GPCR lovers, In pharmacology, the wrong interpretation of antagonist behavior can derail This week in Terry’s Corner , we go beyond the dose-response curves to explore the kinetic and pharmacologic edge by staying on top of the latest breakthroughs in allostery, biased signaling, and computational pharmacology Keywords: GPCR, drug discovery, pharmacology, antagonism, competitive, non-competitive, Terry's Corner #DrugDiscovery #Pharmacology #Biotech #GPCRNews #Science #DrugDevelopment

GPCR – Precision Tools for GPCR Assays Dr. GPCR and Celtarys Research have teamed up. features a discussion about a scalable GPCR-RAMP assay. Their global resource is now helping labs decode GPCR biology at scale. It’s exciting to see how the GPCR field is evolving. GPCR Team

They stall when chemistry, modeling, and pharmacology drift apart. GPCR University Masterclass — Integrated GPCR Discovery in Practice Dr. These sessions span foundational pharmacology, receptor biology, modeling, translational strategy, and advanced GPCR decision logic. Premium Members also receive a 50%+ discount on Terry’s Corner — unlocking advanced pharmacology depth

Career opportunities:  In vitro Pharmacology Research Assistant—Geneva. Why this matters now: PK defines translatability  — activity without exposure is not pharmacology. GPCR podcast , Dr. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need GPCR Team

High-content screening (HCS) has become a cornerstone in GPCR and phenotypic drug discovery, enabling spatial dynamics, and context-dependent signaling significantly influence pharmacology. pharmacology. pharmacology. For teams working in GPCR pharmacology or cannabinoid research, these tools accelerate hit validation

: insights into multireceptor pharmacology for the treatment of metabolic disease Milena Malcharek 10 - 12, 2024 | Pharmacology 2024 NEW January 13 - 16, 2025 | PepTalk 2025 NEW January 25 - 29, 2025 Scientist, GPCR Pharmacology Research Associate - Professor Graeme Milligan Postdoc in Molecular Pharmacology cancer treatment through network pharmacology and molecular docking The Effect of Cancer-Associated : insights into multireceptor pharmacology for the treatment of metabolic disease The role of receptor

Is Your GPCR Program Slowing Down—Even With Good Data? You’re not alone. GPCR Ecosystem. Strong science. Promising data. But no systems to turn it into momentum. GPCR, I’m connected to 1,300+ scientists and decision-makers worldwide. Who I Work With ✅ Biotech Teams  – Especially those lacking in-house GPCR leads or overwhelmed by CRO data chaos. ✅ Venture Capital Firms  – Looking to accelerate, troubleshoot, or validate GPCR assets